SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
694>>CAMBRIDGE, Mass., Nov. 10 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticatuck-11/10/2004
693Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-9mopgcw-11/8/2004
692Vertex Pharmaceuticals Reports Positive Results from 2004-11-01 08:06 (New York)mopgcw-11/1/2004
691Leg: VRTX :3Q04 In Line With Expectations October 26, 2004 RATING: H/3 mopgcw-10/27/2004
690Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in Casaubon-10/19/2004
689Vertex Pharmaceuticals Announces Issuance of Convertible 2004-09-13 18:56 (New Ymopgcw-9/13/2004
688GS: VRTX(U/N) Management update, pipeline making steady progress 52-Week Range mopgcw-8/25/2004
687George. Thanks for the post, as well as the many others that go by without my bfred hayes-8/18/2004
686The Goldman Sachs Biotechnology Team, Maykin Ho, Meg Malloy, and Steve McGarry wmopgcw-8/17/2004
685Leg: Vertex reported a 2Q04 loss per share of $0.54, excluding one-time charges.mopgcw-7/28/2004
684GS: VRTX(UP/N) Q2 solid partner progress 52-Week Range US$15-8 YTD Price Changemopgcw-7/27/2004
683Vertex Pharmaceuticals Reports Second Quarter 2004 Financial 2004-07-26 16:00 (Nmopgcw-7/26/2004
682Leg: VRTX :Telzir (fosamprenavir) Receives Marketing Approval in Euro 2004-07-16mopgcw-7/20/2004
681GS: VRTX (U/N) Merck collaboration - strategic positive 52-Week Range US$16-8 Ymopgcw-6/22/2004
680I suppose the large stock grant incentive to mgt timing of mid May was a heck ofrkrw-6/22/2004
679Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Comnigel bates-6/22/2004
678Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and nigel bates-6/14/2004
677VRTX(U/N) GS conference update - Pipeline progressing 52-Week Range US$16-8 YTDmopgcw-6/14/2004
676Investigational Protease Inhibitor 640385 (VX-385) from GSK and Vertex Indicatesmopgcw-6/8/2004
675Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VXmopgcw-6/8/2004
674Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Ctnsaf-6/3/2004
673Vertex Raised to `Outperform' at Sanford C. Bernstein :VRTX US 2004-06-01 0mopgcw-6/2/2004
672Vertex Pharmaceuticals Announces Plans for the METRO Study: Triple Combination omopgcw-5/25/2004
671Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceutimopgcw-5/24/2004
670LOL!! But maybe if Borger had been Vagelos he would have thrown his statin at okeokalani'nui-5/15/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News